Studies from AstraZeneca Provide New Data on Drug Research (The Effect of Severe Renal Impairment On the Pharmacokinetics, Safety and Tolerability of Mitiperstat).

A new report discusses research conducted by AstraZeneca on the drug Mitiperstat and its effects on patients with impaired renal function. The study assessed the pharmacokinetics, safety, and tolerability of Mitiperstat in participants with severe renal impairment and normal renal function. The findings showed that participants with severe renal impairment had lower clearance of Mitiperstat compared to those with normal renal function. The study concluded that these findings, along with data from phase 2b, will guide the dosing regimen for phase 3. The research has been peer-reviewed and published in the British Journal of Clinical Pharmacology. [Extracted from the article]